CHIPSA 2017 Review: Plans, Partnerships and Advancements In Treatment
2017 was a year of great gains in our treatment of cancer at the CHIPSA Hospital. The CHIPSA Approach™ has been a simple one; forget our ego and preconceived notions of what works in treating cancer and be open to all possibilities. This includes considering both natural and man made medications for the treatment of what is now considered incurable stage 4 cancer.
This approach is a different one than has been used in the past. Our experience tells us that the alternative and conventional sides of medicine have long been at odds with each other as to what is the best treatment. Each side casts giant stones at the other, all the while millions of people are dying of cancer every year.
When CHIPSA Hospital reopened in August of 2015 after being closed for two years, it reopened with part of the old staff, many of whom worked with the legendary pioneer Charlotte Gerson. But it also reopened with a new group of doctors and scientists who are passionate to evolve alongside the latest scientific developments to fight this disease. CHIPSA has used nearly every natural method known and the fact is, in many cases, it simply is not enough. That’s not to say we haven’t seen amazing results in patients who adhere to natural therapies, we simply aren’t satisfied with those results alone.
Last January we hired an award winning oncologist from MD Anderson. This was an unprecedented move for a Mexican hospital and one that drew harsh words from critics of anything conventional. But this moved signaled a change of tide in our relentless pursuit to have the best treatments possible for our patients. This U.S. oncologist was open to alternatives to the status quo and drastically lowering the doses of chemotherapy, while mixing with insulin. He has seen the devastation of high doses of chemotherapy destroying patient’s immune system. And after 30+ years he had enough.
The great start to 2017 gave us the momentum to further our research on Apatone, a combination with the amazing potential of increasing the effectiveness of chemotherapy without toxic side effects. A combination that in some studies has shown to increase the potency of chemotherapy by over 600%. A product that had a phase 1 FDA trial in 2006 that showed great promise but lack of funds kept it from going through the ‘billion dollar’ FDA clinical trial process for market approval. We are proud to say that after 16 months of work and research at CHIPSA, in November of 2017, Mexican based distributor UnoMedica got Apatone approved in Mexico as a supplement. As of the last week of December, Apatone is now available to patients all over the world that want to use it as a supplement with or without chemotherapy.
As we were supporting the development of Apatone we were able to see the true potential and promise of Mexico. Building a bridge to one U.S. oncologist and a small group of scientists working on Apatone was a start, but to make great gains we knew we needed to form great alliances. We believe in a bigger vision. One that aligns our hospital in Mexico with some of the top scientists in the world; fast tracking research and embodying the very meaning of translational medicine.
Last year, we were introduced to the brilliant immunologist Dr. Thomas Ichim. Dr. Ichim had a story that many people who have been through the battle with cancer can relate to. His mom had an incurable form of Leukemia. And Tom, wanting to save his mom, decided to take it upon himself to help her live. He wrote his first patent on Ozone for Leukemia at 18 years old and has since gone on to be published in over 110 peer reviewed journals. He’s been involved in multiple clinical trials. After an 18 year battle Dr. Ichim’s mom passed away from cancer. But this was after she was given just 3 years to live.
Dr. Ichim went on to found Batu Biologics, named after his mother, and to invent ValloVax, continuing the work of the acclaimed Russian scientist Dr. Valentin Govallo. Govallo noticed that a tumor mimicked a baby growing in a placenta. It turns out that the same signals that the placenta gave off to keep the immune system from attacking it were many of the same signals tumors gave off to avoid the immune system. In his book titled, Immunology of Pregnancy and Cancer, Dr. Govallo documented of a 60 percent, 10 year survival rate in patients with various late stage solid tumors. Dr. Ichim has been on a mission to give this treatment its proper chance to prove its efficacy. The team at Batu has defined the mechanisms of action of Govallo’s original therapy and has developed a more potent second generation of the immunotherapy that can be manufactured with batch to batch consistency under GMP.
In October CHIPSA treated our first prostate cancer patient with Vallovax at the end of a 3 week stay at CHIPSA. Though it is still very early in his treatment, the initial result was remarkable and we will include a link at the bottom of the page to read his story. To date we have treated 18 patients with Vallovax and the study is on going.
In 2017 we took on strategic collaborations with 3 companies doing amazing work in oncology and immuno-oncology. These companies, IC-Medtech, Batu Biologics, and Immunicom are on the forefront of innovative treatments. These collaborations have given us access to some of the top scientists in the world who don’t care about the politics of medicine and simply want to cure cancer.
In November, Vallovax received phase 1 FDA clearance to begin a trial at the University of Miami. In 2018 it is our goal to announce two more clinical trials in the United States with treatments we are already using, one of which we’ve used for over 20 years!
2018 is a year we expect to make even more gains in the advancement of treating cancer. Our treatments will combine the very best of nutritional and natural therapies, utilizing cytotoxic agents like Apatone and Insulin Potentiated Therapy [IPT] and cutting edge immunotherapies like checkpoint inhibitors, ValloVax and immunopheresis. Our high quality Coley’s fluid is still the strongest driver of innate immunity that we know of and is one of the longest standing treatments at CHIPSA. We are very excited to further study the synergy between Coley’s and these new immunotherapies as early results have been promising.
The method and timing of these treatments is something that we have followed closely and our methodology will be based off of our understanding of the immune cycle. The average patient will receive IPT every 10 days with Apatone before and after to create maximum damage to the cancer cells. We will prime the immune system before this treatment with Coley’s fluid and other immune modulators. We will stimulate dendritic cells, natural killer cells and macrophages in between this period to recognize and clear as much of the cancer as fast as we possibly can. And we will strategically use Vallovax both in combination with our other treatments and alone with the hope to damage and destroy the blood supply to the tumors.
Our knowledge is gaining traction and momentum everyday and we will take every bit of our experience and knowledge to bring the best treatments we can to our patients.
If you or someone you love would like to see how or if you can utilize the treatments at CHIPSA give us a call at 1-855-624-4772 or click the button below. We will schedule you a free 30 minute appointment to talk to one of our doctors.Click Here To Speak With a Doctor For Free!
Got More Questions ?
Get In Contact With CHIPSA Hospital Directly By Calling 1-855-624-4772 To Speak With A Doctor For Free!